Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Over the last 12 months, insiders at Charles River Laboratories International, Inc. have bought $0 and sold $15.66M worth of Charles River Laboratories International, Inc. stock.
On average, over the past 5 years, insiders at Charles River Laboratories International, Inc. have bought $1.28M and sold $33.91M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,322 shares for transaction amount of $248,298 was made by Girshick Birgit (Corporate Executive VP & COO) on 2023‑11‑20.
2024-11-07 | Sale | director | 7,621 0.0151% | $216.17 | $1.65M | -5.23% | ||
2024-08-08 | Sale | EVP, Corp Strategy & Develop | 1,780 0.0034% | $199.36 | $354,861 | -2.46% | ||
2024-08-01 | Sale | Chairman, President and CEO | 25,000 0.05% | $250.00 | $6.25M | -18.56% | ||
2024-05-15 | Sale | director | 332 0.0007% | $235.62 | $78,225 | -12.39% | ||
2024-05-10 | Sale | EVP, Corp Strategy & Develop | 1,304 0.0025% | $226.97 | $295,969 | -10.40% | ||
2024-03-08 | Sale | CSVP&Chief Accounting Officer | 808 0.0016% | $267.52 | $216,156 | -20.77% | ||
2024-03-04 | Sale | CSVP&Chief Accounting Officer | 2,750 0.0054% | $261.05 | $717,890 | -17.68% | ||
2024-02-29 | Sale | EVP & Chief People Officer | 5,000 0.0097% | $253.70 | $1.27M | -15.80% | ||
2024-02-29 | Sale | CEVP, Disc & Safety Assessment | 3,786 0.0073% | $253.45 | $959,545 | -15.80% | ||
2024-02-22 | Sale | Corporate Executive VP & CCO | 4,050 0.0079% | $248.50 | $1.01M | -13.04% | ||
2024-02-15 | Sale | EVP, Corp Strategy & Develop | 838 0.0016% | $238.93 | $200,223 | -12.23% | ||
2024-02-15 | Sale | CEVP, Disc & Safety Assessment | 5,882 0.0113% | $241.20 | $1.42M | -12.23% | ||
2023-12-14 | Sale | EVP & Chief People Officer | 5,526 0.0106% | $225.00 | $1.24M | -4.05% | ||
2023-11-30 | Sale | EVP, Corp Strategy & Develop | 1,850 0.0036% | $197.73 | $365,801 | +11.10% | ||
2023-11-20 | Corporate Executive VP & COO | 1,322 0.0025% | $187.82 | $248,298 | +14.37% | |||
2023-11-14 | Chairman, President and CEO | 5,620 0.0109% | $178.05 | $1M | +21.69% | |||
2023-11-09 | Sale | EVP, Corp Strategy & Develop | 9,128 0.0182% | $173.48 | $1.58M | +28.79% | ||
2023-08-24 | director | 1,000 0.0019% | $198.79 | $198,786 | +8.50% | |||
2023-08-10 | Sale | EVP, Corp Strategy & Develop | 700 0.0014% | $216.52 | $151,564 | -1.30% | ||
2023-08-10 | Sale | CSVP&Chief Accounting Officer | 1,471 0.0029% | $216.54 | $318,530 | -1.30% |
FOSTER JAMES C | Chairman, President and CEO | 188251 0.3681% | $200.89 | 6 | 84 | +4.13% |
Barbo William D | Corporate Executive VP & CCO | 22879 0.0447% | $200.89 | 0 | 13 | |
LaPlume Joseph W | EVP, Corp Strategy & Develop | 22521 0.044% | $200.89 | 0 | 20 | |
Creamer Victoria L | EVP & Chief People Officer | 13550 0.0265% | $200.89 | 0 | 3 | |
Knell Michael Gunnar | CSVP&Chief Accounting Officer | 7825 0.0153% | $200.89 | 0 | 8 | |
MASSARO GEORGE | director | 5855 0.0114% | $200.89 | 0 | 32 | |
Parisotto Shannon M | CEVP, Disc & Safety Assessment | 4792 0.0094% | $200.89 | 0 | 4 | |
WALLMAN RICHARD F | director | 0 0% | $200.89 | 4 | 13 | +7.27% |
CAWTHORN ROBERT | director | 286700 0.5607% | $200.89 | 0 | 2 | |
JOHST DAVID P | Corporate Executive VP | 212854 0.4162% | $200.89 | 0 | 28 | |
NIMMO WALTER S | director | 149447 0.2923% | $200.89 | 0 | 5 | |
ACKERMAN THOMAS F | 111698 0.2184% | $200.89 | 0 | 41 | ||
RENAUD REAL H | Corp. Executive VP | 63586 0.1243% | $200.89 | 0 | 12 | |
REESE C RICHARD | director | 56457 0.1104% | $200.89 | 0 | 4 | |
Girshick Birgit | Corporate Executive VP & COO | 44449 0.0869% | $200.89 | 1 | 13 | |
CHUBB STEPHEN D | director | 40529 0.0793% | $200.89 | 0 | 40 | |
SHAUGHNESSY DENNIS R | Sr. VP Corporate Development | 37761 0.0738% | $200.89 | 0 | 3 | |
BERTOLINI ROBERT J | director | 29134 0.057% | $200.89 | 0 | 5 | |
MILNE GEORGE M JR | director | 28417 0.0556% | $200.89 | 0 | 10 | |
Smith David Ross | Corporate Executive VP & CFO | 27064 0.0529% | $200.89 | 0 | 28 | |
WALTRIP WILLIAM | director | 21830 0.0427% | $200.89 | 0 | 5 | |
Molho Davide | President & COO | 17155 0.0335% | $200.89 | 0 | 20 | |
BATHGATE BRIAN | Corporate Vice President | 16134 0.0316% | $200.89 | 0 | 8 | |
BERTHOUX CHRISTOPHER | Corp Sr VP | 15047 0.0294% | $200.89 | 0 | 7 | |
THIER SAMUEL O MD | director | 14190 0.0277% | $200.89 | 0 | 17 | |
GELLER JORG | Corporate Executive VP | 14094 0.0276% | $200.89 | 0 | 26 | |
URQUHART JOHN | director | 11738 0.023% | $200.89 | 0 | 2 | |
ELLIOTT DAVID J | Officer | 11750 0.023% | $200.89 | 0 | 1 | |
GILLETT NANCY | Corporate Executive VP | 11034 0.0216% | $200.89 | 1 | 41 | +0.49% |
Ho John C | Senior Vice President | 8950 0.0175% | $200.89 | 1 | 0 | +15.04% |
Kochevar Deborah Turner | director | 6096 0.0119% | $200.89 | 0 | 10 | |
Crowley John J | SVP, Chief Accounting Officer | 5883 0.0115% | $200.89 | 0 | 3 | |
ROGERS DOUGLAS E | director | 5349 0.0105% | $200.89 | 0 | 1 | |
ANKCORN MICHAEL F | Corp. Sr. VP | 0 0% | $200.89 | 0 | 3 | |
MCEWAN ALASTAIR STUART | Corporate VP | 0 0% | $200.89 | 0 | 3 |
The Vanguard Group | $1.64B | 11.74 | 6.05M | +1.11% | +$17.93M | 0.03 | |
BlackRock | $1.4B | 10.04 | 5.17M | +0.2% | +$2.82M | 0.03 | |
State Street | $567.4M | 4.07 | 2.09M | +1.67% | +$9.3M | 0.02 | |
KAYNE ANDERSON INVESTMENT MANAGEMENT LLC | $508.74M | 3.65 | 1.88M | +7.09% | +$33.7M | 1.18 | |
ClearBridge Investments | $409.98M | 2.94 | 1.51M | +3.07% | +$12.21M | 0.33 | |
T. Rowe Price | $358.32M | 2.57 | 1.32M | -8.37% | -$32.71M | 0.04 | |
Geode Capital Management | $320.48M | 2.3 | 1.19M | +3.48% | +$10.77M | 0.03 | |
Meritage Group LP | $320.34M | 2.3 | 1.18M | +2.33% | +$7.29M | 7.55 | |
Allspring Global Investments | $303.14M | 2.17 | 1.12M | -3.99% | -$12.6M | 0.48 | |
Ariel Investments | $252.74M | 1.81 | 932,807 | -11.22% | -$31.94M | 2.49 | |
Mackenzie Financial Corp | $252.47M | 1.81 | 931,797 | +1.52% | +$3.78M | 0.34 | |
EARNEST Partners | $242.16M | 1.74 | 893,761 | +0.49% | +$1.19M | 1.11 | |
Invesco | $241.83M | 1.73 | 892,524 | -5.88% | -$15.12M | 0.05 | |
Bank of America | $240.92M | 1.73 | 889,170 | +20.79% | +$41.47M | 0.02 | |
Southpoint Capital Advisors Lp | $189.66M | 1.36 | 700,000 | -30% | -$81.28M | 3.75 | |
Marshall Wace | $179.6M | 1.29 | 662,849 | New | +$179.6M | 0.18 | |
Franklin Templeton Investments | $176.61M | 1.27 | 651,805 | -14.57% | -$30.13M | 0.05 | |
SEI Investments Company | $155.89M | 1.12 | 575,349 | +1.26% | +$1.94M | 0.23 | |
Wells Fargo | $154.28M | 1.11 | 569,415 | +4.38% | +$6.47M | 0.04 | |
Thrivent Financial For Lutherans | $153.32M | 1.1 | 565,864 | +27.79% | +$33.34M | 0.32 | |
Montrusco Bolton Investments Inc | $132.7M | 0.95 | 489,751 | -32.18% | -$62.95M | 1.42 | |
Dimensional Fund Advisors | $126.64M | 0.91 | 467,393 | -3.02% | -$3.94M | 0.03 | |
Fidelity Investments | $125.93M | 0.9 | 464,765 | +22.54% | +$23.16M | 0.01 | |
Victory Capital Management Inc | $124.59M | 0.89 | 459,818 | -1.66% | -$2.1M | 0.13 | |
Northern Trust | $124.43M | 0.89 | 459,251 | -4.4% | -$5.73M | 0.02 | |
Congress Asset Management Co Ma | $122.85M | 0.88 | 453,392 | -2.55% | -$3.22M | 0.88 | |
Charles Schwab | $121.6M | 0.87 | 448,809 | -12.55% | -$17.45M | 0.03 | |
Morgan Stanley | $117.88M | 0.85 | 435,059 | -7.85% | -$10.04M | 0.01 | |
Fil Ltd | $107.58M | 0.77 | 397,045 | -40.08% | -$71.97M | 0.11 | |
BNY Mellon | $104.05M | 0.75 | 384,023 | -3.17% | -$3.41M | 0.02 | |
William Blair Investment Management | $98.79M | 0.71 | 364,614 | -1.62% | -$1.62M | 0.26 | |
JPMorgan Chase | $96.03M | 0.69 | 354,428 | +55.8% | +$34.39M | 0.01 | |
Luther King Capital Management | $95.16M | 0.68 | 351,205 | -4.26% | -$4.23M | 0.43 | |
Legal & General | $88.43M | 0.63 | 326,362 | -1.61% | -$1.44M | 0.02 | |
Van Berkom Associates Inc | $84.39M | 0.61 | 311,466 | -2.18% | -$1.88M | 2.4 | |
Envestnet Asset Management Inc | $83.36M | 0.6 | 307,663 | +14.56% | +$10.59M | 0.03 | |
Riverbridge Partners | $82.31M | 0.59 | 303,778 | +1.03% | +$836,692.96 | 1.01 | |
Ameriprise Financial | $76.61M | 0.55 | 282,736 | +1,098.8% | +$70.22M | 0.02 | |
PRIMECAP Management Co | $74.22M | 0.53 | 273,930 | 0% | +$0 | 0.05 | |
Neuberger Berman | $72.28M | 0.52 | 266,823 | +3.57% | +$2.49M | 0.06 | |
Jackson Square LLC | $68.09M | 0.49 | 251,308 | -28.09% | -$26.6M | 2.93 | |
Raymond James Associates | $67.29M | 0.48 | 248,348 | +1.91% | +$1.26M | 0.05 | |
Epoch Investment Partners Inc | $67.06M | 0.48 | 247,501 | +2,733.44% | +$64.69M | 0.3 | |
Woodley Farra Manion Portfolio Management | $65.88M | 0.47 | 243,160 | +129.31% | +$37.15M | 3.63 | |
Bellevue Group | $62.24M | 0.45 | 229,697 | +5.48% | +$3.24M | 0.95 | |
Ubs Asset Management Americas Inc | $59.79M | 0.43 | 220,686 | +0.34% | +$201,044.90 | 0.02 | |
Citigroup | $54.9M | 0.39 | 202,617 | +11.51% | +$5.67M | 0.04 | |
Voya Investment Management LLC | $54.39M | 0.39 | 200,730 | -0.04% | -$19,237.45 | 0.06 | |
Boston Trust Walden Corp | $52.82M | 0.38 | 194,939 | -1.23% | -$655,699.00 | 0.38 | |
Fisher Asset Management Llc | $50.03M | 0.36 | 184,655 | -0.95% | -$479,852.73 | 0.02 |